|
US2019336561A1
|
|
Methods for preparing botanical extracts
|
|
WO2018132759A1
|
|
Compounds and methods use
|
|
CA3032453A1
|
|
Pharmaceutical formulations and their use
|
|
US2020179319A1
|
|
Pharmaceutical formulations and their use
|
|
TW201726123A
|
|
Formulations for increasing gene expression
|
|
AU2015332434A1
|
|
Tryptamide compositions and methods of use
|
|
CN104610109A
|
|
ANTI-BACTERIAL AGENTS and composites thereof
|
|
CA2787339A1
|
|
Anti-inflammatory complexes
|
|
AU2009314165A1
|
|
Isoprenyl compounds and methods thereof
|
|
CA2758424A1
|
|
Tryptamine derivatives as pp2a methylation modulators
|
|
CN101945886A
|
|
Employing contains the topical composition and the method for the peptide of lipid-modified halfcystine
|
|
EP2252277A2
|
|
Acetyl mimic compounds for the inhibition of isoprenyl-s-cysteinyl methyltransferase
|
|
WO2009094534A1
|
|
Improved method for preparing isoprenyl cysteine compounds and analogs thereof
|
|
AU2008333929A1
|
|
Acid mimic compounds for the inhibition of isoprenyl-S-cysteinyl methyltransferase
|
|
US2008213406A1
|
|
Compositions and methods for enhancing cognitive function
|
|
WO2006135894A1
|
|
Compositions and methods for treating inflammatory conditions
|
|
WO2006084033A1
|
|
Compositions and methods for enhancing cognitive function
|
|
MXPA06014514A
|
|
Topical compositions and methods for epithelial-related conditions.
|
|
CA2477604A1
|
|
Modulation of protein methylation and phosphoprotein phosphate
|
